Use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli

Abstract

The present disclosure relates to the use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli bacteria, the thiosulfate being in a quantity of at least 100 mg for 10 7 to 10 10 CFU of lactobacilli. The disclosure also relates to a pharmaceutical composition including at least 100 mg of thiosulfate per gram, in combination with a Lactobacillus crispatus strain, and to its use in the treatment of urogenital infections such as vaginosis, candidosis and urinary tract infections.

1 - 9 . (canceled) 
     
     
         10 . A method of using thiosulfate, the method comprising potentiating an anti-pathogenic effect of lactobacilli bacteria with the thiosulfate to treat urogenital infections such as vaginosis, candidiasis and urinary tract infections, the thiosulfate being in a quantity of at least 100 mg/gram of powder, for a powder including from 10 7  to 10 10  CFU/g of lactobacilli. 
     
     
         11 . The method according to  claim 10 , wherein the thiosulfate is selected from sodium thiosulfate or potassium thiosulfate. 
     
     
         12 . The method according to  claim 10 , further comprising using the thiosulfate in a quantity of about 230 mg/gram of powder, for a powder including between 10 7  and 10 10  CFU/g. 
     
     
         13 . The method according to  claim 10 , wherein the lactobacilli are  Lactobacillus rhamnosus  and/or  Lactobacillus crispatus.    
     
     
         14 . A pharmaceutical composition comprising at least 100 mg of thiosulfate per gram, in combination with a  Lactobacillus crispatus  strain. 
     
     
         15 . A pharmaceutical composition comprising a culture supernatant of a  Lactobacillus  strain cultivated in the presence of sodium thiosulfate, the supernatant not containing lactobacilli. 
     
     
         16 . The pharmaceutical composition according to  claim 14 , formulated for vaginal or oral administration. 
     
     
         17 . The pharmaceutical composition according to  claim 14 , adapted to treat urogenital infections such as vaginosis, candidosis and urinary tract infections. 
     
     
         18 . A pharmaceutical composition comprising at least 100 mg of thiosulfate per gram, in combination with 10 7  to 10 10  CFU/g of a  Lactobacillus  strain, adapted to treat urogenital infections such as vaginosis, candidosis and urinary tract infections, by potentiation of the anti-pathogenic effect of lactobacilli.